Biophytis

Biophytis deploys its partnership strategy and signs two contracts with local agents in Asia

Biophytis obtains IND approval from the FDA to start its phase 2 OBA study in obesity

Biophytis presented its Phase 2-3 COVA study results in severe forms of Covid-19 at the WCID in Paris

Biophytis grants Blanver exclusive rights to BIO101 in Latin America in deal valued at up to €108 Million

Biophytis extends its contract with Atlas to secure financing for its business activities

Biophytis announces the successful industrial transfer of BIO101 (20-hydroxyecdysone) production by its service provider Seqens

Biophytis announces filing of an IND application with the US FDA for its phase 2 study in obesity

Combined General Meeting of June 24, 2024

Biophytis announces the design of its phase 2 OBA clinical study in obesity

Biophytis is deploying its partnership strategy in obesity

Biophytis Announces Transfer of ADSs to OTC Market

Biophytis announces ratio change under its American Depositary Receipt (“ADR”) program

Biophytis announces new Scientific Advisory Board for its phase 2 OBA clinical study in obesity

Biophytis announces its 2023 financial results and provides an update on its business activities

Biophytis announces its 2023 financial results and provides an update on its business activities

Biophytis launches OBA phase 2 clinical study in obesity with BIO101 (20-hydroxyecdysone)

RESULTS OF THE COMBINED GENERAL MEETING ON APRIL 2, 2024

Biophytis presented its phase 3 protocol in the treatment of sarcopenia

Biophytis announces receipt of Nasdaq Notice

Biophytis and Innovation Solutions Pharma sign a partnership agreement to accelerate market access for Sarconeos (BIO101) in Brazil

Biophytis receives notice of delisting from Nasdaq and announces it will request a hearing before the Nasdaq Hearings Panel

Biophytis releases its half-yearly accounts as of 30 June 2023 and provides an update on its operations

Biophytis and Skyepharma sign a Partnership Agreement for the Production of Sarconeos (BIO101)

Biophytis provides an update on its early access programs for Sarconeos (BIO101) in the treatment of severe forms of COVID-19

Biophytis Strengthens its Management Team with the Appointment of its Chief Business Officer

Biophytis obtains FDA Authorization to initiate the SARA-31 phase 3 study in sarcopenia

Biophytis to Participate at the H.C. Wainwright 25th Global Investment Conference in New York

Biophytis announces next regulatory steps in Europe and the United States for its COVA project

Biophytis receives a positive opinion for its SARA-31 phase 3 study in sarcopenia in Europe

Biophytis: Biophytis has requested a pre-submission meeting with the FDA for an Emergency Use Authorization of Sarconeos (BIO101) for the treatment of COVID-19